MacroGenics Inc - Company Profile
Powered by 
All the sales intelligence you need on MacroGenics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MacroGenics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MacroGenics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MacroGenics Catalyst Calendar
Proactively evaluate MacroGenics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of MacroGenics Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 01 Dec 2019 | Phase I Trial Initiation | MacroGenics Inc | MGNX | flotetuzumab; retifanlimab | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Company Press Release |
| 01 Dec 2019 | Phase III Trial Initiation | Baxter International Inc; MacroGenics Inc; Zai Lab Ltd | BAX; MGNX; ZLAB | margetuximab | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Metastatic Breast Cancer | Clinical Trial Registry |
| 01 Dec 2019 | Phase II Trial Results | American Diabetes Association; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Juvenile Diabetes Research Foundation; MacroGenics Inc; National Center for Research Resources; National Institute of Health; The Hospital for Sick Children; The National Institute of Allergy and Infectious Diseases; The National Institute of Diabetes and Digestive and Kidney Diseases; TrialNet; U.S. National Institutes of Health | MGNX | teplizumab | Metabolic Disorders | Pre-Diabetes/Impaired Glucose Tolerance; Type 1 Diabetes (Juvenile Diabetes) | Company Presentation |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer